Regenxbio price target lowered to $14 from $25 at BofA

BofA lowered the firm’s price target on Regenxbio (RGNX) to $14 from $25 and keeps a Buy rating on the shares. The firm views the RGX-202 AFFINITY DUCHENNE topline update as “directionally encouraging despite some questions about safety and regulatory path,” but reduced its peak penetration estimate and view of the odds of success for DMD due to regulatory uncertainty despite what it calls “an objectively positive topline result from the study.”